Laura Hamid, Chief Executive Officer, and Dominique Pichard, MD, MS, Chief Scientific and Medical Officer of the International Rett Syndrome Foundation (IRSF), discuss the changing treatment landscape for Rett syndrome and the organization’s commitment to supporting patients and their families.
Understanding Rett Syndrome
Rett syndrome is a rare, genetic neurodevelopmental disorder caused by a mutation in the MECP2 gene. It occurs in about 1 in 10,000 births worldwide. Although Rett syndrome most commonly affects females, males can also have the condition.
Infants with Rett syndrome typically achieve normal developmental milestones for the first six to 18 months of their lives, but then begin to lose previously acquired skills, such as language and motor coordination, during the regression phase. Potential complications of Rett syndrome include seizures, abnormal breathing patterns, scoliosis, and gastrointestinal issues.
A New Era of Treatment for People with Rett Syndrome
Dr. Pichard shared that for many years, families who had a child with Rett syndrome didn’t have many treatment options, other than supportive care. That changed on March 10, 2023, when the U.S. Food and Drug Administration (FDA) approved Daybue (trofinetide) as the first and only therapy for Rett syndrome in adult and pediatric patients ages two years and older.
Trofinetide has given families an effective treatment option that makes it easier for some Rett patients to pay attention, communicate, interact, and engage with the world around them. However, Ms. Hamid emphasized that just because the drug works for some patients, it doesn’t necessarily mean that it’s a solution for everyone. “There’s a saying that when you’ve seen one individual with Rett syndrome, you’ve seen one individual with Rett syndrome,” she said. “It’s a very complex, heterogeneous disease.”
Because one treatment can’t meet every patient’s needs, Dr. Pichard and Ms. Hamid shared that IRSF is building a “medicine cabinet” of potential therapies.
Supporting Families Throughout the Rett Syndrome Journey
In addition to finding new treatment options, IRSF supports families and Rett syndrome patients from early diagnosis through adulthood. Rett-related symptoms change significantly over time, so Dr. Pichard and Ms. Hamid said the organization tries to meet people where they’re at.
For families dealing with a new diagnosis, IRSF provides mentors with first-hand experience navigating the condition. On the other end of the spectrum, the organization offers support for families with loved ones transitioning to adult care by finding appropriate housing and planning for aging caregivers. This focus on the continuity of care ensures people with Rett syndrome and their families receive the assistance they need, regardless of age or life stage.
Expanding Recognition and Research for Males with Rett Syndrome
Another focus of IRSF is raising awareness about males with Rett syndrome. Historically, Rett was viewed as a condition primarily affecting females, but advances in genetic testing have helped researchers confirm that boys and men are also impacted.
A 2025 study partially funded by IRSF found that only about one-third of males with Rett syndrome meet the classic diagnostic criteria. Dr. Pichard and Ms. Hamid said this finding highlights just how many people have previously gone undiagnosed.
Ms. Hamid also explained that feedback from families about their male loved ones being left out of research and treatment development prompted IRSF to take action. The organization established MR. | Males with Rett Fund, a $1 million fund dedicated to research including males with Rett syndrome. The fund will support initiatives to increase male participation in clinical trials, develop objective outcome measures, raise awareness, and improve diagnostic criteria.
Improving Research to Bring More Treatments to Families
Last, Dr. Pichard and Ms. Hamid discussed IRSF’s focus on and investment in academic research and early-stage therapeutic development. They shared that there are more than 20 biopharmaceutical companies currently working on Rett syndrome treatments in various stages of development.
They also discussed the formation of the Rett Syndrome Registry, which aims to collect longitudinal data from individuals across the disease spectrum. More specifically, the registry contains clinician- and caregiver-reported information as well as clinical assessment tools used in clinical trials. Dr. Pichard and Ms. Hamid said this data will help researchers and pharmaceutical companies advance drug development and identify regulatory pathways.
In Their Own Words
“When you look at the community, I look at an energized group of people who know that there’s something better coming on the horizon and who are ready. Having a community that is educated and understanding of what’s coming at them is important. Having a community that is energized to be available, to be connected, and to take on the difficulties and fear of these new medicines. That’s not nothing. It’s real.” – Laura Hamid, Chief Executive Officer, IRSF
To learn more about Rett syndrome and other rare genetic neurodevelopmental disorders, visit: https://checkrare.com/diseases/neurology-nervous-system-diseases/

